Celularity Inc. (CELU)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 3
Do Nothing: fundamentalScore 1 and qualitativeScore 1 both fail the required >=3 override floors (going-concern distress, Nasdaq 5250(c)(1) non-compliance); recent 3-session average dollar volume $0.75M is also below the $1.5M recent-liquidity floor (the $25.1M 20-day average is surge-skewed by the 08-27 +89% spike).
Company overview
Celularity Inc. is a clinical-stage biotechnology company focused on developing allogeneic cell therapies from placental sources. Its therapeutic pipeline targets cancers, immune disorders, and infectious diseases, with key candidates in various trial phases. The company also offers surgical and wound care products and stem cell storage services.
Fundamental
very weakCelularity faces severe financial distress with negative equity, liquidity issues, and going-concern doubts.
Too risky to invest: Celularity's FY2025 10-K contains explicit going-concern substantial doubt (management, Note 1, and auditor), negative stockholders' equity, recurring operating losses with negative operating and free cash flow, multiple debt defaults and forbearances, Nasdaq delisting of its warrants plus a bid-price deficiency notice, and late 10-Qs for both 2026 interim periods. Asset sales (NexGel, New Jersey NOLs) provided temporary cash but do not resolve the solvency risk.
Sentiment
very weakSentiment is dominated by regulatory and going-concern overhangs, despite a recent positive market reaction to a collaboration deal.
Dominant near-term catalyst is bearish — the Nasdaq Listing Rule 5250(c)(1) non-compliance notice (regulator_confirmed, 2026-08-25) for unfiled Q1/Q2 10-Qs — offset by the market-rewarded MuseCell manufacturing collaboration (announced, ≈+126% pop, 2026-08-27). Sentiment delta is indeterminate (30–90d baseline returned zero scorable items on a degraded enrichment-timeout pull) while the 14d window reads determinate-but-mixed at ≈ +0.22 (n=8, aggregator tier); severe red-flag cap applied on going-concern/auditor doubt, which remains unresolved in-window (NT 10-Q 2026-08-14, filings still outstanding).
Technical
fairTechnicals show a recent spike and bullish moving averages, but liquidity and fundamental issues prevent actionable trades.
Chart scored 3 (mixed): a fully bullish moving-average stack and positive MACD are offset by cooling momentum (RSI fading from 92.6 to 64.95), a -8.2% last completed session, and a post-spike volume collapse. Regardless of the chart, the trade is routed Do Nothing by the hard override gates (fundamentalScore 1, qualitativeScore 1) and the recent-liquidity gate; no trade plan is built.
You’re looking at 2026-09-07 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.